Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multi‐protein cascade of the complement system

Abstract excerpt

Over a century after the discovery of the complement system, the first complement therapeutic was approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). It was a long-acting monoclonal antibody (aka 5G1-1, 5G1.1, h5G1.1, and now known as eculizumab) that targets C5, specifically preventing the generation of C5a, a potent anaphylatoxin, and C5b, the first step in the eventual formation of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adenosine and Purinergic Signaling
• Share to Complement system in diseases
• Share to Renal Diseases and Glomerulopathies